16 articles for ZF Tao
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Abbvie
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Abbvie
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Genentech
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.

Abbott Laboratories
Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.

Abbott Laboratories
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Abbvie
Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors.

Abbott Laboratories
Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability.

Abbott Laboratories
Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.

Abbott Laboratories
Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.

Abbott Laboratories
1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies.

Abbott Laboratories
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X

Abbvie
Structure-Based Design of A-1293102, a Potent and Selective BCL-X

Abbvie
Imidazopyridazine derivatives as PI3KB inhibitors

Janssen Pharmaceutica
Metalloenzyme inhibitor compounds

Viamet Pharmaceuticals (Bermuda)
5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa.

Bristol-Myers Squibb Pharmaceutical Research Institute